Moderna Inc. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 57.20
Dividend & YieldN/A£ (N/A)
Beta 1.69
Market capitalization N/A
Operating cash flow 9.65B
ESG Scores unknown

Company description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -50.24M -68M 3.85B 3.03B
Total Cashflows From Investing Activities -373.09M -15M -1.67B -8.52B
Net Borrowings 9.46M 1M -6M -140M
Total Cash From Financing Activities 1.23B 52M 2.03B -873M
Change To Operating Activities 6.83M 8M 156M 582M
Issuance Of Stock 564.45M 51M 2.04B 124M
Net Income -384.73M -514M -747M 12.2B
Change In Cash 522.88M -422M 2.39B 4.22B
Effect Of Exchange Rate
Total Cash From Operating Activities -330.87M -459M 2.03B 13.62B
Depreciation 24.86M 31M 93M 232M
Change To Account Receivables 832k 7M -1.39B -1.78B
Other Cashflows From Financing Activities
Change To Netincome 71.59M 77M 103M -122M
Capital Expenditures -105.77M -32M -68M -284M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -384.41M -515M -744M 13.29B
Net Income -384.73M -514M -747M 12.2B
Selling General Administrative 94.25M 110M 188M 567M
Gross Profit -319.01M -436M -575M 13.86B
Ebit -413.27M -546M -763M 13.3B
Operating Income -413.27M -546M -763M 13.3B
Interest Expense -3.1M -10M -10M -18M
Income Tax Expense 326k -1M 3M 1.08B
Total Revenue 135.07M 60M 803M 18.47B
Cost Of Revenue 454.08M 496M 1.38B 4.61B
Total Other Income ExpenseNet 28.86M 31M 19M -11M
Net Income From Continuing Ops -384.73M -514M -747M 12.2B
Net Income Applicable To Common Shares -401.86M -514M -747M 12.2B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 431.91M 414.61M 4.78B 10.52B
Total Stockholder Equity 1.53B 1.17B 2.56B 14.14B
Other Current Liabilities 124.61M 68.82M 3.87B 7.14B
Total Assets 1.96B 1.59B 7.34B 24.67B
Common Stock 33k 34k
Other Current Assets 595k 1.03M 228M 481M
Retained Earnings -1.01B -1.5B -2.24B 9.96B
Treasury Stock -1.32M 1.8M 3M -24M
Cash 658.36M 235.88M 2.62B 6.85B
Total Current Liabilities 222.8M 143.12M 4.39B 9.13B
Other Stockholder Equity -1.32M 1.8M 3M -24M
Property, Plant, and Equipment 211.98M 287.91M 387M 1.38B
Total Current Assets 1.56B 1.13B 6.3B 16.07B
Net Tangible Assets 1.53B 1.17B 2.56B 14.14B
Net Receivables 30.58M 16.3M 1.41B 3.3B
Accounts Payable 31.21M 7.09M 18M 302M


Insider Transactions

Here are the insider transactions of stock shares related to Moderna Inc.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BANCEL STEPHANE JSale at price 118.98 - 128.73 per share.D/I2022-10-20Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-20Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 132.50 per share.D2022-10-19Director10k
BANCEL STEPHANE JSale at price 126.51 - 135.43 per share.D/I2022-10-13Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-13Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 135.36 per share.D2022-10-12Director10k
BANCEL STEPHANE JSale at price 122.40 - 126.31 per share.D/I2022-10-06Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-10-06Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 122.40 per share.D2022-10-05Director10k
BANCEL STEPHANE JSale at price 115.76 - 124.36 per share.D/I2022-09-29Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-29Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 123.58 per share.D2022-09-28Director10k
BANCEL STEPHANE JSale at price 124.20 - 131.44 per share.D/I2022-09-22Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-22Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 130.37 per share.D2022-09-21Director10k
BANCEL STEPHANE JSale at price 136.14 - 141.31 per share.D/I2022-09-15Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-15Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 134.00 per share.D2022-09-14Director10k
HOGE STEPHENSale at price 136.42 - 141.66 per share.D2022-09-13President6.97k
HOGE STEPHENConversion of Exercise of derivative security at price 10.90 per share.D2022-09-13President6.97k
BANCEL STEPHANE JSale at price 133.02 - 142.15 per share.D/I2022-09-08Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-08Chief Executive Officer80k
KLINGER SHANNON THYMESale at price 137.44 per share.D2022-09-08Officer478
AFEYAN NOUBAR BOGHOSSale at price 129.68 per share.D2022-09-07Director10k
KLINGER SHANNON THYMED2022-09-07Officer1.14k
BANCEL STEPHANE JSale at price 131.13 - 137.24 per share.D/I2022-09-01Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-09-01Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 136.95 per share.D2022-08-31Director10k
HOGE STEPHENSale at price 135.81 per share.D2022-08-29President1.12k
ANDRES JUANSale at price 135.81 per share.D2022-08-29Chief Technology Officer839
HOGE STEPHEND2022-08-26President2.41k
ANDRES JUAND2022-08-26Chief Technology Officer1.81k
BANCEL STEPHANE JSale at price 138.48 - 143.08 per share.D/I2022-08-25Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-08-25Chief Executive Officer80k
HOGE STEPHENSale at price 141.70 - 142.80 per share.D2022-08-24President10k
HOGE STEPHENConversion of Exercise of derivative security at price 10.90 per share.D2022-08-24President10k
BANCEL STEPHANE JSale at price 149.34 - 161.91 per share.D/I2022-08-18Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-08-18Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 165.24 per share.D2022-08-17Director10k
ANDRES JUANSale at price 165.24 per share.D2022-08-17Officer2k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-08-17Officer2k
HOGE STEPHENSale at price 172.68 - 172.85 per share.D2022-08-15President10k
HOGE STEPHENConversion of Exercise of derivative security at price 10.90 per share.D2022-08-15President10k
BANCEL STEPHANE JSale at price 170.93 - 179.54 per share.D/I2022-08-11Chief Executive Officer90k
BANCEL STEPHANE JConversion of Exercise of derivative security at price 0.99 per share.D2022-08-11Chief Executive Officer80k
AFEYAN NOUBAR BOGHOSSale at price 174.09 per share.D2022-08-10Director10k
MELINE DAVID WSale at price 173.66 per share.D2022-08-10Chief Financial Officer164
HOGE STEPHENSale at price 173.66 per share.D2022-08-10President244
ANDRES JUANSale at price 173.66 - 174.09 per share.D2022-08-10Chief Technology Officer2.2k
ANDRES JUANConversion of Exercise of derivative security at price 20.93 per share.D2022-08-10Chief Technology Officer2.44k
MELINE DAVID WD2022-08-09Chief Financial Officer348

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Moderna Inc.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Moderna Inc.

Here is the result of two systematic investment strategies applied to Moderna Inc.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Moderna Inc.

The following chart shows the equity curve of the two systematic investment strategies applied to Moderna Inc.:

Moderna Inc. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Moderna Inc.

This is the result of two momentum investment strategies applied to Moderna Inc.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Moderna Inc.

The following chart shows all the entries opened by the momentum investment system on Moderna Inc.:

Moderna Inc. momentum entries
  • The first momentum investment strategy would give -35.54% of return on Moderna Inc.. That represents -124.53£ of latent gain with 350.39£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Moderna Inc.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

-35.54 %

Latent gain

-124.53 £

Invested capital

350.39 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Moderna Inc.

The following chart shows the equity curve of the two momentum strategies applied to Moderna Inc.:

Moderna Inc. momentum equity

Note: the dividends potentially given by Moderna Inc. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Moderna Inc.

The following chart shows the employed capital evolution of the two momentum strategies on Moderna Inc. since the beginning:

Moderna Inc.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Moderna Inc.

Buy the dip entry openings on Moderna Inc.

Moderna Inc.

The performance achieved by the robo-advisor on Moderna Inc. is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Moderna Inc. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Moderna Inc., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Moderna Inc.

The following chart shows the result of the investment strategy applied to Moderna Inc.:

Moderna Inc.

Note: the dividends potentially given by Moderna Inc. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Moderna Inc.

The following chart shows the employed capital evolution since the beginning of the investment strategy on Moderna Inc.:

Moderna Inc.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Moderna Inc.

In this section, I will compare the three previous investment strategies applied to Moderna Inc..

Equity curve comparison on Moderna Inc.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Moderna Inc. investment strategy comparison

Employed capital comparison on Moderna Inc.

Moderna Inc. investment comparison

Performance comparison on Moderna Inc.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter -35.54% -124.53£ 350.39£ -888.5%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Moderna Inc.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Moderna Inc. and the other stocks. There may be false positives or some missing correlated stocks. If the price of Moderna Inc. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Moderna Inc.
Country United States
City Cambridge
Address 200 Technology Square
Phone 617 714 6500
Website www.modernatx.com
FullTime employees 3400
Industry
Sector
Exchange XLON
Ticker 0A45.XLON
Market www.londonstockexchange.com

Moderna Inc. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown